• Home
  • Search Results

Search Results

Young Adult (18-34)
2376 studies match your search

Characterization of Circulating Tumor DNA Kinetics During Radiation Therapy, Treatment Monitoring, and Surveillance: A Pilot Study in Hematologic and Pediatric Malignancies

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Age & Gender
  • 2 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Pediatric Cancers, Lymphoma)
Open

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Do you have ovarian cancer that has come back after your first round of treatment? if so you may be able to participate in a research study to test if MIRV in combination with bevacizumab as maintenance therapy, can help to prevent your cancer from returning or delaying your cancer's return.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Other Cancers, Ovarian)
Not currently enrolling

This study tests whether CT-155 improves negative symptoms associated with schizophrenia.

This study tests whether the investigational device CT-155 improves negative symptoms associated with schizophrenia.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Chronic Conditions
  • Mental and Emotional Health
Not currently enrolling

Dupilumab for Eosinophilic Esophagitis with Severe Strictures (DESTRICT Study)

To determine the effect of an FDA-approved drug on treating patients with severe strictures and Eosinophilic Esophagitis (EoE)

Age & Gender
  • 16 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Stomach, Digestion and Gut Health
  • Ear, Nose, and Throat
Open

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)

A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer

To determine the change from baseline to post-treatment values in HR-positive, HER2-negative invasive lobular carcinoma tissue derived from postmenopausal women awaiting definitive surgery or further treatment.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
Not currently enrolling

Eosinophilic Esophagitis Study

Researchers want to learn more a new medication that could be used to treat adults with Eosinophilic Esophagitis (also called "EoE").

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Allergy
  • Chronic Conditions
  • Stomach, Digestion and Gut Health
  • Eating, Nutrition, and Metabolism

Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions

To determine the difference in change in apoptosis between diagnosis and surgery as a function of ruxolitinib treatment versus placebo, among participants with high-risk or premalignant breast conditions.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Study of sacituzumab govitecan with or without pembrolizumab in Metastatic TNBC

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Radiation, PARP inhibition, and immunotherapy for breast cancer brain metastasis

Have you been diagnosed with breast cancer with brain metastases? If so, you may be able to take part in a research study looking at the safety of giving a new drug called olaparib concurrently (at the same time) with stereotactic radiosurgery, followed by immunotherapy and chemotherapy, to patients with breast cancer with brain metastases.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
  • Cancer (Brain and Other Nervous System, Breast)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research